CSPC Innovation Pharmaceutical (SHE:300765) subsidiary CSPC Jushi Biopharmaceutical's phase 3 trial for its SYS6010 lung cancer drug reached its primary endpoint of progression-free survival, according to a Thursday disclosure to the Shenzhen Stock Exchange.
The drug exhibited better progression-free survival than current treatments, with statistically and clinically significant differences, as well as good safety, the filing said.